Arylsulfonamide ethers, and methods of use thereof

Details Arylsulfonamide ethers, and methods of use thereof Arylsulfonamide ethers, and methods of use thereof

2005-04-05

2005-04-05

McKenzie, Thomas C. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S252120, C514S303000, C514S311000, C514S312000, C514S307000, C514S331000, C514S365000, C514S368000, C514S394000, C514S400000, C514S405000, C514S562000, C544S159000, C544S399000, C546S118000, C546S149000, C546S157000, C546S172000, C546S235000, C548S154000, C548S204000, C548S308700, C548S309700, C548S338500, C548S362500, C562S430000

Reexamination Certificate

active

06875765

ABSTRACT:
The novel arylsulfonamide ether compounds, pharmaceutical compositions and uses thereof as inhibitors of interleukin-1β converting enzyme and other cysteine proteases in the ICE family are described. In one embodiment, the compound is described by the generalized structure:and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof. In addition, methods of treating stroke, inflammatory diseases, septic shock, repurfusion injury, Alzheimer's disease, and shigellosis, using a compound of the invention or a pharmaceutical composition thereof, are described.

REFERENCES:
patent: WO 9816504 (1998-04-01), None
patent: WO 9816504 (1998-04-01), None
Wolff, Manfred E. “Burger's Medicinal Chemistry, 5ed, Part I”, John Wiley & Sons, 1995, pp. 975-977.*
Banker, G.S. et al, “Modern Pharmaceutics, 3ed.”, Marcel Dekker, New York, 1996, pp. 451 and 596.*
Randle, J.C. et al, Expert Opin. Investig. Drugs, 2001, vol. 10(7), pp. 1207-1209, Medline Abstract 11772244.*
Giegel, D.A. et al, Ann. Reports Med. Chem., 33, 1998, 183-192.*
Siegmund, B., Biochem. Pharmacol., vol. 64(1), 2002, pp. 1-8, Medline Abstract 12106600.*
Alnemri, E.S. et al. “Human ICE/CED-3 Protease Nomenclature.”Cell87:171 (Oct. 18, 1996).
Berge, S.M. et al. “Pharmaceutical Salts.”Journal of Pharmaceutical Sciences66(1):1-19 (Jan. 1977).
Ghayur, T. et al. “Caspase-1 Processes IFN-γ-inducing Factor and Regulates LPS-induced IFN-γ Production.”Nature386:619-23 (Apr. 10, 1997).
Harvey, R.G. et al. “Synthesis of the Dihydrodiol and Diol Epoxide Metabolites of Chrysene and 5-Methylcrhysene.”J. Org. Chem51:1407-1412 (1986).
Kouzai, Hiroaki et al. “Polymerization of 1-(1-Naphthyl)-1-Propyne by Nb and Ta Catalysts and Polymer Properties: Effects of the 1-Naphthyl Group.”Bull. Chem. Soc. Jpn.68:398-402 (1995).
Lai, G. et al. “A Concise Synthesis of a Benzimidazole Analogue of Mycophenolic Acid using a BF3-Et2O catalyzed amino-Claisen rearrangement.”Tetrahedron Letters34(43):6849-52 (1993).
Thornberry, N.A. et al. “Interleukin-1β-converting enzyme and related proteases as potential targets in inflammation and apoptosis.”Perspectives in Drug Discovery and Design2:389-99 (1994).

Affiliated with

Also associated with

Rating

Arylsulfonamide ethers, and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Arylsulfonamide ethers, and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Arylsulfonamide ethers, and methods of use thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3375768